In the second quarter of 2023 there is a noticeable recovery in the number of provided medicines after a decline in the winter period, which indicates a continuing trend of their increase compared to previous years, according to the press release of the insurance company “INGO” (Kiev).
It is also noted that the analysis of the popularity of services showed a continued increased demand for diagnostics since September 2022. At the same time consultations of doctors remain at a stable level without significant changes.
The other groups of services, although accounting for less than 20% of the total, do not show pronounced changes, with the exception of medical examinations, the demand for which has doubled in recent months compared to the preliminary figures.
According to the report, for the provision of medical services to its clients in the second quarter of 2023 paid UAH 110 million. The amount of payments for accident insurance programs has also increased.
According to the information of the Department of personal types of insurance, the average number of customer contacts is kept at a fairly high level – about 1.5 thousand contacts daily, but a little less than in the winter-spring period.
JSC INGO Insurance Company has more than 25 years of experience in the market. Since 2017, the main shareholder of the company is the Ukrainian business group DCH of Oleksandr Iaroslavskyi.
The company has 29 licenses for various types of compulsory and voluntary insurance, provides insurance services to corporate and retail clients.
The Dobrobut medical network has launched the second stage of the program of free medications for oncology patients.
The nursing network informed Interfax-Ukraine that the program is implemented with the support of Direct Relief International Charitable Foundation.
During the second stage of the program providing free drugs for cancer patients will be able to get drugs for pancreatic, intestinal and breast cancer – Cyclophosphamide 500mg, Cyclophosphamide 1g made in USA and Fluorouracil 50mg made in UK.
“Patients who are diagnosed with breast cancer or colon cancer or pancreatic cancer and prescribed the appropriate drug can receive the drug,” the company specified.
“Dobrobut” is one of the largest private medical networks in Ukraine. It consists of 17 medical centers in Kyiv and Kyiv region, emergency service, dentistry and pharmacy. Medical centers of network provide services for children and adults in more than 75 medical directions. Annually experts of “Dobrobut” carry out more than 7000 operations. The network has over 2,800 employees.
Collaborates with a number of international charities Direct Relief International, Children of War Foundation, International Medical Corps and the University of Miami Global Institute, as well as the Dobrobut Foundation, a charitable foundation founded by the clinic.
Imports of drugs to Ukraine in 2022, after five years of growth, decreased by 38% compared to the previous year – to $ 1.9 billion from $ 3.1 billion.
This is evidenced by the research conducted by the marketing agency Top Lead together with the pharmaceutical company “Darnitsa”.
According to the study, the largest importers of medicines to Ukraine are Germany with the import volume of about $ 368 million, India ($ 173 million), France ($ 31 million), Italy ($ 125 million) and Slovenia ($ 110 million).
At the same time, export of Ukrainian medicines in 2022 decreased by 24% as compared with 2021, and amounted to $ 238 million.
The biggest buyer of Ukrainian medicines is Uzbekistan, where Ukrainian companies exported products worth almost $52m, which is 36% less than a year earlier.
At the same time, other top three buyers of Ukrainian medicines increased export – Kazakhstan by 12% (to $ 32 million), Lithuania – by 324% ($23 million).
“In 2022, Ukrainian companies stopped selling medicines to Russia and Belarus, export to Lithuania and Latvia increased. But despite this, most of the Ukrainian pharmaceutical export goes to Asia”, – report’s authors emphasize.
They also noted that, although the largest manufacturers of medicines in Ukraine have GMP-certificates issued by Gosleksluzhba, that confirm the production and control of drugs in accordance with international quality standards, the EU does not yet recognize these certificates. “Therefore, to export to the EU, a manufacturer has to undergo an additional check by the regulatory authorities of one or another EU country. The task for Ukraine in the near future is to achieve recognition of Ukrainian certificates in the EU,” the authors of the study stressed.
Swiss pharmaceutical company Acino became a partner of the project “Mobile hospitals for Victory” implemented by Charitable Foundation for Reconstruction and Development of Ukraine.
According to the press release from the Foundation, within the framework of this project Acino shipped to the pilot mobile medical complex 1600 packages of drugs from its own product portfolio for the total amount of UAH 150 thousand.
The “Mobile Hospitals for Victory” project provides for purchasing 52 mobile hospitals. The cost of one such medical complex on wheels is EUR 240 thousand.
Currently 14 organizations in Ukraine and abroad have joined the project.
Mobile hospital is a complete hospital on wheels equipped with modern medical equipment. It consists of an admission room, a laboratory, an X-ray room, an operation room and also technical rooms, toilets and showers. The hospital is equipped with its own generator. Two medical teams can work there at the same time, with the ability to save up to 100 lives a day, based on the “golden hour” principle.
Since the beginning of Russia’s full-scale invasion of Ukraine on February 24, 2022, the Acino pharmaceutical company has donated more than 67 million UAH for humanitarian purposes, including over 200 thousand packages of medicines to hospitals and hospitals in the country.
Sales of medicines in 2022 amounted to 46 billion UAH.
According to the company SMD, according to their study, in particular, in the retail segment in the category of pharmaceuticals market decline was 37% in volume and 28% in money terms.
At the same time in public procurement the fall in drug sales was 26% in volume and 21% in monetary terms.
“Despite the difficult situation, the state has even increased budgetary support and already one third of the entire drug market has state funding. Also the share of reimbursement has increased significantly due to the expansion of the program “Affordable Medicines” in such categories as diabetes (insulin), mental and behavioral disorders”, – the company said.
As reported, the Ukrainian pharmaceutical market in 2022 decreased by 42% in volume terms and by 23% in monetary terms, the cumulative sales in the pharmaceutical market in 2022 amounted to about 61 billion UAH in pharmacy entrance prices.
The Verkhovna Rada (Ukrainian parliament) has adopted a bill on limiting the circulation of medicines produced in the Russian Federation and Belarus (registration No. 7313).
The adoption of bill No. 7313 at the final reading at a session on Tuesday was supported by 316 MPs with the required 226 votes, Yaroslav Zhelezniak, a member of the Holos parliamentary faction, said on his Telegram channel.
As reported, bill No. 7313, which restricts the circulation of medicines produced in the Russian Federation or the Republic of Belarus, and authored by a group of MPs of the Servant of the People faction, including Head of the committee on national health, medical care and medical insurance Mykhailo Radutsky, was registered in the Rada on April 25, 2022.
According to First Deputy Minister of Health Oleksandr Komarida, state registration of medicines (all or selectively determined by the Ministry of Health) of an applicant in Ukraine can be temporarily canceled (registration certificate terminated) if it is established that this applicant or his representative is directly or indirectly related to business entities who are directly or indirectly involved in the production of medicines on the territory of the aggressor state (the Russian Federation or the Republic of Belarus).
In addition, the registration of the drug may be canceled if, after February 23, 2022, the applicant participated in at least one of the stages of production of any medicinal product or active pharmaceutical ingredients by an enterprise located on the territory of the aggressor state.
